Biophytis Presented Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference
Portfolio Pulse from Benzinga Newsdesk
Biophytis presented positive results of its phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 patients at the American Thoracic Society International Conference. The company focuses on therapeutics that slow degenerative processes associated with aging, including severe respiratory failure in COVID-19 patients.
May 25, 2023 | 7:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biophytis presented positive results of its phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 patients, potentially boosting investor confidence in the company's therapeutics.
The positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 patients indicate that Biophytis' therapeutics may be effective in treating severe respiratory failure associated with COVID-19. This could lead to increased investor confidence in the company's potential for growth and success, resulting in a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100